Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort

Abstract The objective of this study was to determine risk factors predicting seizures and damage caused by seizures in a multi-ethnic systemic lupus erythematosus cohort (PROFILE) that includes systemic lupus erythematosus patients (n = 1295) from five different US institutions. Only patients with seizures after systemic lupus erythematosus diagnosis (incident) were included in the analyses of clinical seizures (80/1295, 6.2%), but all patients (prevalent and incident) were included in the analyses of damage caused by seizures (51/1295, 3.9%). We examined socioeconomic–demographic, clinical, and genetic variables predictive of clinical seizures and damage from seizures by Cox proportional hazard ratios (HR) and 95% confidence intervals (CI). Independent predictors of a shorter time to the occurrence of clinical seizures were younger age (HR = 1.0; 95% CI 0.9–1.0), having Hispanic-Texan ethnicity (HR = 2.7; 95% CI 1.3–5.7) or African-American ethnicity (HR = 1.8; 95% CI 1.0–3.1), and the previous occurrence of a cerebrovascular accident (HR = 3.3; 95% CI 1.6–7.1) or an episode of psychosis (HR = 2.4; 95% CI 1.1–5.0), whereas the previous occurrence of photosensitivity (HR = 0.5; 95% CI 0.3–0.9) was the only independent predictor of a longer time to the occurrence of clinical seizures. Independent predictors of a shorter time to the occurrence of damage caused by seizures were younger age (HR = 1.0; 95% CI 0.9–1.0), male gender (HR = 2.4; 95% CI 1.1–5.4), and the occurrence of a previous cerebrovascular accident (HR = 2.7; 95% CI 1.0–7.0) or an episode of psychosis (HR = 4.7; 95% CI 2.3–9.9). No allele from the candidate genes examined (HLA-DRB1, HLA-DQB1, FCGR2A, FCGR3A, or FCG3B) predicted clinical seizures or damage caused by seizures.

[1]  I. Bruce,et al.  Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. , 2007, Arthritis and rheumatism.

[2]  D. Dlugos,et al.  Role of genetics in the diagnosis and treatment of epilepsy , 2006, Expert review of neurotherapeutics.

[3]  Gerald McGwin,et al.  Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus Cohort , 2006, PLoS medicine.

[4]  I. Scheffer,et al.  De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study , 2006, The Lancet Neurology.

[5]  Marta E Alarcón-Riquelme,et al.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus , 2006, Nature Genetics.

[6]  R. Kimberly,et al.  SLE: challenges and candidates in human disease. , 2005, Trends in immunology.

[7]  R. Kimberly,et al.  Genetics of susceptibility and severity in systemic lupus erythematosus , 2005, Current opinion in rheumatology.

[8]  J. Mikdashi,et al.  Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus , 2005, Neurology.

[9]  A. Delgado-Escueta,et al.  Sacred disease secrets revealed: the genetics of human epilepsy. , 2005, Human molecular genetics.

[10]  J. Harley,et al.  Genetics of human systemic lupus erythematosus: the emerging picture. , 2004, Current opinion in immunology.

[11]  F. Cendes,et al.  Epileptic seizures in systemic lupus erythematosus , 2004, Neurology.

[12]  J. Hanly,et al.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. , 2004, The Journal of rheumatology.

[13]  G. Hughes,et al.  Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. , 2003, The Journal of rheumatology.

[14]  C. Langefeld,et al.  Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[15]  W. Brooks,et al.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[16]  G. Gronseth,et al.  Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions , 2002, Neurology.

[17]  M. Petri,et al.  Baseline characteristics of a multiethnic lupus cohort: PROFILE , 2002, Lupus.

[18]  A. Auvinen,et al.  Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. , 2001, Arthritis and rheumatism.

[19]  H. Bastian,et al.  Sociocultural issues in clinical research. , 2001, Arthritis and rheumatism.

[20]  D. Gladman,et al.  The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. , 2000, The Journal of rheumatology.

[21]  J. Piette Updating the American College of Rheumatology criteria for systemic lupus erythematosus: comment on the letter by Hochberg. , 1998, Arthritis and rheumatism.

[22]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[23]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[24]  J G Bodmer,et al.  HLA class II region nucleotide sequences, 1995. , 1995, Tissue antigens.

[25]  J G Bodmer,et al.  HLA class II region nucleotide sequences. , 1995, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[26]  C. Bombardier,et al.  Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. , 1994, The Journal of rheumatology.

[27]  J. Reveille,et al.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). , 1992, The Journal of clinical investigation.

[28]  M. Liang,et al.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[29]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.